SCHEMBL21494746

SCHEMBL21494746

Nc1ccc(C(=O)O)nc1-c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.52
ALOX15 P16050 2/20 0.52
TSHR P16473 1/20 0.52
ACMSD Q8TDX5 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
MGAM O43451 1/20 0.47
MAP2K3 P46734 1/20 0.45
CNR1 P21554 1/20 0.44
PLAU P00749 2/20 0.43
CYP1A2 P05177 2/20 0.43
ECE1 P42892 2/20 0.43
CYP2C9 P11712 1/20 0.43
TBXA2R P21731 1/20 0.43
CYP2C19 P33261 1/20 0.43
PTGER1 P34995 1/20 0.43
LMNA P02545 3/20 0.42
NAPRT Q6XQN6 1/20 0.42
P4HTM Q9NXG6 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
DHODH Q02127 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23030228 0.82 ALDH1A1 (0.51) KDM4ELMNAALDH1A1HPGDHSD17B10
SCHEMBL2837730 0.79 KDM4E (0.54) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL16698002 0.78 KDM4E (0.52) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL319073 0.78 KDM4E (0.52) KDM4EALOX15TSHRACMSDTDP1
Dipicolinic Acid SCHEMBL23071472 0.76 KDM4E (0.81) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL30712642 0.76 CNR1 (0.66) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL4456253 0.76 CNR1 (0.66) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL28283758 0.74 KDM4E (0.50) KDM4EALOX15TSHRACMSDTDP1
SCHEMBL20657581 0.73 PIN1 (0.44) KDM4ETSHRMAP2K3PLAULMNA
SCHEMBL19857475 0.72 KDM4E (0.48) KDM4EALOX15TSHRACMSDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12357634-B2 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2025-07-15 US disclosed
CN-112218858-B 2, 6-Diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy 托马斯·黑勒戴药物研究基金会 2024-06-18 CN disclosed
EP-3781554-B1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) 2023-06-28 EP disclosed
EP-3781554-B1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FOER MEDICINSK FORSKNING (SE) 2023-06-28 EP disclosed
US-20230110478-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2023-04-13 US disclosed
US-11504368-B2 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2022-11-22 US disclosed
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY MEDICINSK FORSKNING (SE) 2021-02-25 US disclosed
EP-3781554-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY Thomas Helledays stiftelse för medicinsk forskning (SE) 2021-02-24 EP disclosed
CN-112218858-A 2, 6-diamino-3, 4-dihydropyrimidin-4-one derivatives and their use in therapy 托马斯·黑勒戴药物研究基金会 2021-01-12 CN disclosed
WO-2019201991-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2019-10-24 WO disclosed
WO-2019201991-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2019-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11504368-B2 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy IL2, THPO, IL6 KDM4E 2274/4885ALOX15 1551/4885TSHR 4655/4885
US-20230110478-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY IL2, THPO, IL6 KDM4E 2175/4885ALOX15 1796/4885TSHR 4631/4885
US-12357634-B2 2,6-diamino-3,4-dihydropyrimidin-4-one derivatives and use thereof in therapy IL2, THPO, IL6 KDM4E 2175/4885ALOX15 1796/4885TSHR 4631/4885
US-20210052587-A1 2,6-DIAMINO-3,4-DIHYDROPYRIMIDIN-4-ONE DERIVATIVES AND USE THEREOF IN THERAPY IL2, THPO, IL6 KDM4E 2274/4885ALOX15 1551/4885TSHR 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.